Innate Pharma S.A.

IPHANASDAQHealthcare● Active

$1.76

+$0.05(+2.92%)

Market Cap$165269787

P/E Ratio—

52W High$2.63

52W Low$1.17

Avg Volume68K

Open$1.73

Beta0.89

Overview

Innate Pharma S.A. (IPHA) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

IPHA · net income · updated Jun 9, 2026

Core profitability metrics

IPHA · net income · margin · TTM · CAGR

Net income was −$49.2M for FY2025 (fiscal year ending 2025-12-31), up 0.6% year-over-year. Net profit margin was -1764.5%. Based on available data, Innate Pharma S.A. has been profitable since at least 2016.

FY2025 Net Income−$49.2M▲ +0.6% YoY

Trailing 12M (TTM)−$98.4Mtrailing 4 quarters sum

Net Profit Margin< −999%−$49.2M ÷ $2.8M

YoY Change+0.6%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2016

▸ FMP /income-statement · Annual · IPHA net income history · IPHA profit margin

Annual net income data

IPHA · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$49.2M▲ +0.6%-1764.5%$2.8M

FY2024Loss−$49.5M▼ 553.5%-392.0%$12.6M

FY2023Loss−$7.6M▲ +87.0%-14.6%$51.9M

FY2022Loss−$58.1M▼ 10.0%-100.7%$57.7M

FY2021Loss−$52.8M▲ +17.5%-436.0%$12.1M

Net income vs peers (Healthcare)

IPHA vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Innate Pharma S.A.YOU

IPHA

−$49.2M+0.6%-1764.5%

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Innate Pharma S.A. (IPHA) reported net income of −$49.2M for FY2025 (fiscal year ending 2025-12-31), up 0.6% year-over-year. The net profit margin was -1764.5% — meaning the company kept $-17.65 of every dollar of revenue as profit.

Based on available data, Innate Pharma S.A. has been profitable since at least 2016. Net income reached a peak of $12.6M in FY2016. Data available for 15 fiscal years.

Innate Pharma S.A.'s net profit margin was -1764.5% for FY2025, based on the latest annual results.

Investors sometimes search for "Innate Pharma S.A. net worth" — the company's market capitalization is a separate figure from IPHA net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

IPHA net income · 4 questions

Innate Pharma S.A. is not currently profitable on an annual basis. The company reported a net loss of $49.2M for FY2025.

is IPHA profitabledoes IPHA make a profitIPHA profitabilityIPHA profitable company

▸ Source: FMP /income-statement · GAAP · Innate Pharma S.A. · Innate Pharma S.A. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026